CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.2904
-0.0061 (-2.06%)
At close: Apr 25, 2025, 4:00 PM
0.2831
-0.0073 (-2.51%)
Pre-market: Apr 28, 2025, 6:25 AM EDT
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
24.43M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
CVM News
- 4 days ago - CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Business Wire
- 19 days ago - New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses - Business Wire
- 4 weeks ago - CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients - Business Wire
- 5 weeks ago - CEL-SCI Announces Closing of $2.5 Million Offering - Business Wire
- 5 weeks ago - CEL-SCI Announces Pricing of $2.5 Million Offering - Business Wire
- 5 weeks ago - CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Business Wire
- 6 weeks ago - Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression - Business Wire
- 2 months ago - CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Business Wire